<span item_type="fundamental" item_id="1ce443935524ed4f62d6d4ab4f2c9f9b" counter_id="ST/US/RCKTW" env="prod"></span><span item_type="announcement" item_id="513929770088799745" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.56.</p><p></p><h3>Cash Position</h3><ul><li>Cash, cash equivalents, and investments as of March 31, 2025, were $318.2 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm"></span></li></ul><h3>Research and Development (R&amp;D) Expenses</h3><ul><li>R&amp;D expenses were $35.9 million for the three months ended March 31, 2025, compared to $45.2 million for the same period in 2024, marking a decrease of $9.3 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm"></span></li></ul><h3>General and Administrative (G&amp;A) Expenses</h3><ul><li>G&amp;A expenses were $28.4 million for the three months ended March 31, 2025, compared to $22.1 million for the same period in 2024, an increase primarily due to commercial preparation, legal expenses, and non-cash stock compensation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss was $61.3 million or $0.56 per share for the three months ended March 31, 2025, compared to $62.1 million or $0.66 per share for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm"></span></li></ul><h3>Total Assets and Liabilities</h3><ul><li>Total assets as of March 31, 2025, were $471.1 million, with total liabilities of $58.9 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Rocket Pharmaceuticals expects its cash, cash equivalents, and investments to be sufficient to fund operations into the fourth quarter of 2026, including the production of AAV cGMP batches and continued development of its clinical and preclinical programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_ex99-1.htm"></span></li></ul>

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM) | 8-K: FY2025 Q1 EPS: USD -0.56